Oric Pharmaceuticals, Inc. (ORIC) stock
ORICNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.86−0.64 (-7.53%)
Close on Nov 13, 2026Market cap $814.71MP/E –Yield –
Oric Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Oric Pharmaceuticals's total assets was $404.69M at Jun 30, 2026. For fiscal 2025 it was $408.89M, up 49.2% from the year before. The highest annual figure on record is $408.89M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $408.89M | +49.2% |
| FY2024 | Dec 31, 2024 | $274.14M | +8.8% |
| FY2023 | Dec 31, 2023 | $252.01M | +2.0% |
| FY2022 | Dec 31, 2022 | $247.18M | -17.2% |
| FY2021 | Dec 31, 2021 | $298.64M | -0.1% |
| FY2020 | Dec 31, 2020 | $299.00M | +217.8% |
| FY2019 | Dec 31, 2019 | $94.09M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $404.69M | +16.7% |
| Q1 FY2026 | Mar 31, 2026 | $436.76M | +79.8% |
| Q4 FY2025 | Dec 31, 2025 | $408.89M | +49.2% |
| Q3 FY2025 | Sep 30, 2025 | $431.19M | +42.7% |
| Q2 FY2025 | Jun 30, 2025 | $346.86M | +5.5% |
| Q1 FY2025 | Mar 31, 2025 | $242.86M | -30.8% |
| Q4 FY2024 | Dec 31, 2024 | $274.14M | +8.8% |
| Q3 FY2024 | Sep 30, 2024 | $302.07M | +10.1% |
| Q2 FY2024 | Jun 30, 2024 | $328.91M | +12.7% |
| Q1 FY2024 | Mar 31, 2024 | $350.79M | +54.8% |
| Q4 FY2023 | Dec 31, 2023 | $252.01M | +2.0% |
| Q3 FY2023 | Sep 30, 2023 | $274.34M | +15.3% |
| Q2 FY2023 | Jun 30, 2023 | $291.82M | +12.4% |
| Q1 FY2023 | Mar 31, 2023 | $226.65M | -17.6% |
| Q4 FY2022 | Dec 31, 2022 | $247.18M | -17.2% |
| Q3 FY2022 | Sep 30, 2022 | $238.00M | -24.2% |
| Q2 FY2022 | Jun 30, 2022 | $259.68M | -3.2% |
| Q1 FY2022 | Mar 31, 2022 | $275.06M | -3.1% |
| Q4 FY2021 | Dec 31, 2021 | $298.64M | -0.1% |
| Q3 FY2021 | Sep 30, 2021 | $314.18M | +63.9% |
| Q2 FY2021 | Jun 30, 2021 | $268.23M | +33.1% |
| Q1 FY2021 | Mar 31, 2021 | $283.96M | +233.9% |
| Q4 FY2020 | Dec 31, 2020 | $299.00M | +217.8% |
| Q3 FY2020 | Sep 30, 2020 | $191.66M | – |
| Q2 FY2020 | Jun 30, 2020 | $201.53M | – |
| Q1 FY2020 | Mar 31, 2020 | $85.06M | – |
| Q4 FY2019 | Dec 31, 2019 | $94.09M | – |
See a number that looks wrong?